At MannKind Corporation (NASDAQ: MNKD), we focus on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension.Over twenty-five years ago, in February 1991, the company – now known as MannKind Corporation—was founded. Originally incorporated as Pharmaceutical Discovery Corporation (PDC) in Elmsford, New York, it developed its Technosphere® technology, a versatile drug delivery platform that allows the pulmonary administration of therapeutics currently requiring administration by injection, shortly after its formation.In the mid-1990s, Alfred Mann – at the time, CEO of MiniMed Inc. – started working with PDC through a collaborative research effort and eventually became a significant shareholder. In 2001, the company merged with two other companies owned by Alfred Mann (CTL Immunotherapies Corp. and Allecure Corp.) and the surviving company changed its name to MannKind Corporation. As a result of this merger, we relocated the corporate headquarters to Valencia, California while focusing the East coast operations – by this time, located in Danbury, Connecticut – on improving the Technosphere® technology and developing our innovative line of delivery devices.
|Bank Name||MannKind Corporation|
|CEO||Dr. Michael E. Castagna|